Skip to main content

ADVERTISEMENT

Poster

27 year old male with history of HIV infection and substance abuse disorder arrived at the ER presenting aggressive behavior, errors of judgment and conduct, ego dystonic complex, auditor...
10/26/2023
3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy is being investigated as a potential treatment option for patients with posttraumatic stress disorder (PTSD). Previous animal MDM...
10/26/2023
This pooled post hoc analysis compared the effects of a combination of olanzapine and samidorphan (OLZ/SAM) versus olanzapine on body weight after 12 weeks of treatment in patients with s...
10/26/2023
This analysis evaluated extrapyramidal symptoms (EPS) across 2 pooled, 6-week, placebo-controlled monotherapy studies; a 6-month open-label extension (OLE) monotherapy study; and a 6-week...
10/26/2023
This randomized, double-blind, placebo-controlled trial investigated the efficacy and safety of lumateperone 42mg for the treatment of a major depressive episode in patients with major de...
10/26/2023
This meta-analysis aimed to assess the treatment effect of maintenance transcranial magnetic stimulation for depression. The analysis included 14 studies and 705 participants. Maintenance...
10/26/2023
TV-46000 is a long-acting subcutaneous antipsychotic (LASCA). The SHINE study evaluated the long-term safety, tolerability, and effect of TV-46000 once monthly (q1m) and once every two mo...
10/26/2023
This subgroup analysis of SUSTAIN-3 (NCT02782104), a phase 3, open-label extension study of esketamine nasal spray (ESK), assessed the long-term efficacy of flexibly dosed ESK in combinat...
10/26/2023
In a long-term study (up to 6.6 years) of intermittently-dosed esketamine with daily antidepressant, early improvement in depression was maintained and no new safety signal was identified...
10/26/2023
This subgroup analysis of SUSTAIN-3 (NCT02782104), an open-label extension study of esketamine nasal spray (ESK), assessed the long-term safety of flexibly dosed ESK in combination with a...
10/26/2023